Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer

Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer

(2021) Xing-mei Liang et al.   ACTA PHARMACOLOGICA SINICA

Cystine supplementation rebalances the redox homeostasis of microenvironment in non-small cell lung cancer cells and reverses their resistance to docetaxel

(2021) Si-jia Li et al.   ACTA PHARMACOLOGICA SINICA

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Boronic acid with high oxidative stability and utility in biological contexts

(2021) Brian J. Graham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma

(2021) Min Luo et al.   Acta Pharmaceutica Sinica B

PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway

(2021) Mei-sa Wang et al.   ACTA PHARMACOLOGICA SINICA

Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer

(2021) Jamie E. Chaft et al.   Nature Reviews Clinical Oncology

An RFC4/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness

(2021) Lei Liu et al.   Nature Communications

GSH-sensitive polymeric prodrug: Synthesis and loading with photosensitizers as nanoscale chemo-photodynamic anti-cancer nanomedicine

(2021) Lei Luo et al.   Acta Pharmaceutica Sinica B

Influencing factors and strategies of enhancing nanoparticles into tumors in vivo

(2021) Mingming Zhang et al.   Acta Pharmaceutica Sinica B

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

(2021) Umair Majeed et al.   Journal of Hematology & Oncology

Light-controllable charge-reversal nanoparticles with polyinosinic-polycytidylic acid for enhancing immunotherapy of triple negative breast cancer

(2021) Lei Fang et al.   Acta Pharmaceutica Sinica B

New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer

(2020) Huiping Qiang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Development of amine-functionalized superparamagnetic iron oxide nanoparticles anchored graphene nanosheets as a possible theranostic agent in cancer metastasis

(2020) Mahesh P. More et al.   Drug Delivery and Translational Research

HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells

(2020) Qian Liang et al.   ACTA PHARMACOLOGICA SINICA

Application of targeted therapy strategies with nanomedicine delivery for atherosclerosis

(2020) Le-chun Ou et al.   ACTA PHARMACOLOGICA SINICA

The EZH2-PHACTR2-AS1-ribosome axis induces genomic instability and promotes growth and metastasis in breast cancer

(2020) Wenhui Chu et al.   CANCER RESEARCH

NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.

(2020) Makoto Maemondo et al.   JOURNAL OF CLINICAL ONCOLOGY

MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer

(2020) Jia-lin Shang et al.   ACTA PHARMACOLOGICA SINICA

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

(2020) Josep Garcia et al.   CANCER TREATMENT REVIEWS

The Effect of Advances in Lung-Cancer Treatment on Population Mortality

(2020) Nadia Howlader et al.   NEW ENGLAND JOURNAL OF MEDICINE

The progress and perspective of nanoparticle-enabled tumor metastasis treatment

(2020) Wei Zhang et al.   Acta Pharmaceutica Sinica B

Molecular engineering of antibodies for site-specific conjugation to lipid polydopamine hybrid nanoparticles

(2020) Hobin Yang et al.   Acta Pharmaceutica Sinica B

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer

(2020) Rong Wang et al.   Nature Communications

VEGFR2-targeted antibody fused with IFN mut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity

(2020) Pengzhao Shang et al.   Acta Pharmaceutica Sinica B

GSH-responsive SN38 dimer-loaded shape-transformable nanoparticles with iRGD for enhancing chemo-photodynamic therapy

(2020) Congcong Lin et al.   Acta Pharmaceutica Sinica B

Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab

(2020) Doan T. M. Ngo et al.   Journal of Clinical Medicine

The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer

(2020) Chao Zhao et al.   Translational Lung Cancer Research

Role of Glutathione in Cancer: From Mechanisms to Therapies

(2020) Luke Kennedy et al.   Biomolecules

Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype

(2020) Monique B. Nilsson et al.   Journal of Thoracic Oncology

Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations

(2020) Antonio Passaro et al.   Journal of Thoracic Oncology

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

(2019) Haruhiro Saito et al.   LANCET ONCOLOGY

Overview of recent advances in liposomal nanoparticle-based cancer immunotherapy

(2019) Ang Gao et al.   ACTA PHARMACOLOGICA SINICA

Cationic lipoplexes for treatment of cancer stem cell-derived murine lung tumors

(2019) Terrick Andey et al.   Nanomedicine-Nanotechnology Biology and Medicine

Engineering nanoparticles to locally activate T cells in the tumor microenvironment

(2019) Dangge Wang et al.   Science Immunology

Corona Composition Can Affect the Mechanisms Cells Use to Internalize Nanoparticles

(2019) Valentina Francia et al.   ACS Nano

5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study

(2019) Yung-Hung Luo et al.   LANCET ONCOLOGY

Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non–Small Cell Lung Cancer

(2019) Thomas E. Stinchcombe et al.   JAMA Oncology

A Nanoemulsion with A Porphyrin Shell for Cancer Theranostics

(2019) Wenxiu Hou et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

1480OCTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC

(2019) Q Zhou et al.   ANNALS OF ONCOLOGY

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Kazuhiko Nakagawa et al.   LANCET ONCOLOGY

Overview of current systemic management of EGFR-mutant NSCLC

(2018) W -H Hsu et al.   ANNALS OF ONCOLOGY

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

(2018) Shang-Gin Wu et al.   Molecular Cancer

Disulfide Bond-Driven Oxidation- and Reduction-Responsive Prodrug Nanoassemblies for Cancer Therapy

(2018) Bingjun Sun et al.   NANO LETTERS

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

(2018) Rajeswara Rao Arasada et al.   Nature Communications

The architecture of EGFR’s basal complexes reveals autoinhibition mechanisms in dimers and oligomers

(2018) Laura C. Zanetti-Domingues et al.   Nature Communications

Emerging functions of the EGFR in cancer

(2017) Sara Sigismund et al.   Molecular Oncology

Tumor Microenvironment Responsive Nanogel for the Combinatorial Antitumor Effect of Chemotherapy and Immunotherapy

(2017) Qingle Song et al.   NANO LETTERS

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

(2017) et al.   Cancers

Proteome- pI : proteome isoelectric point database

(2016) Lukasz P. Kozlowski   NUCLEIC ACIDS RESEARCH

Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery

(2016) A Dokala et al.   ONCOGENE

Impact of bevacizumab in combination with erlotinib onEGFR-mutated non-small cell lung cancer xenograft models with T790M mutation orMETamplification

(2015) Koh Furugaki et al.   INTERNATIONAL JOURNAL OF CANCER

IL-6 Antibody and RGD Peptide Conjugated Poly(amidoamine) Dendrimer for Targeted Drug Delivery of HeLa Cells

(2015) Shewaye Lakew Mekuria et al.   JOURNAL OF PHYSICAL CHEMISTRY B

Principles of nanoparticle design for overcoming biological barriers to drug delivery

(2015) Elvin Blanco et al.   NATURE BIOTECHNOLOGY

Cationic Bovine Serum Albumin Based Self-Assembled Nanoparticles as siRNA Delivery Vector for Treating Lung Metastatic Cancer

(2013) Jianfeng Han et al.   Small

Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle

(2013) Shruti R Saptarshi et al.   JOURNAL OF NANOBIOTECHNOLOGY

Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor

(2012) S Yoshikawa et al.   ONCOGENE

EGFR Mutations and Lung Cancer

(2011) Gilda da Cunha Santos et al.   Annual Review of Pathology-Mechanisms of Disease

DNA affects the composition of lipoplex protein corona: A proteomics approach

(2011) Anna L. Capriotti et al.   PROTEOMICS

Liposome triggering of innate immune responses: A perspective on benefits and adverse reactions

(2009) Janos Szebeni et al.   JOURNAL OF LIPOSOME RESEARCH